← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,246	+84	+7%	$67.1B
2	2 Danaher DHR $158B	1,200	+83	+7%	$50.5B
3	3 Novartis NVS $279B	1,007	+69	+7%	$21.1B
4	4 Agilent Technologies A $49.1B	652	+32	+5%	$18.6B
5	5 Illumina ILMN $41B	644	+68	+12%	$29.4B
6	6 Regeneron Pharmaceuticals REGN $80.1B	639	+33	+5%	$26.9B
7	7 Revvity RVTY $17B	398	+48	+14%	$7.44B
8	8 Charles River Laboratories CRL $14.4B	339	+3	+0.9%	$5.16B
9	9 Ionis Pharmaceuticals IONS $7.1B	316	+15	+5%	$5.72B
10	10 DELISTED bluebird bio BLUE	296	+53	+22%	$9.29B
11	11 Alnylam Pharmaceuticals ALNY $30B	282	+46	+19%	$11.7B
12	12 DELISTED CATALENT, INC. CTLT	276	-10	-3%	$5.48B
13	13 Sarepta Therapeutics SRPT $1.78B	254	+21	+9%	$3.07B
14	14 Myriad Genetics MYGN $397M	250	+30	+14%	$2.56B
15	15 Bruker BRKR $8.47B	233	+32	+16%	$3.5B
16	16 Azenta AZTA $1.63B	217	0	0%	$1.53B
17	17 Qiagen QGEN $9.41B	215	0	0%	$4.43B
18	18 DELISTED SANGAMO THERAPEUTICS INC SGMO	170	+22	+15%	$916M
19	19 Precigen PGEN $2.64B	163	+8	+5%	$1.13B
20	20 Ultragenyx Pharmaceutical RARE $1.47B	163	+9	+6%	$2.01B
21	21 Editas Medicine EDIT $349M	151	+35	+30%	$934M
22	22 PTC Therapeutics PTCT $4.98B	125	-4	-3%	$636M
23	23 Lineage Cell Therapeutics LCTX $232M	117	+15	+15%	$125M
24	24 Intellia Therapeutics NTLA $1.6B	112	+27	+32%	$467M
25	25 Pacific Biosciences PACB $619M	109	+11	+11%	$205M